Researchers at NYU’s Grossman School of Medicine found patients given the antimalarial drug hydroxychloroquine along with zinc sulphate and the antibiotic azithromycin were 44 percent less likely to die from the coronavirus.
The study looked at the records of 932 COVID-19 patients treated at local hospitals with hydroxychloroquine and azithromycin.
More than 400 of them were also given 100 milligrams of zinc daily.
Researchers said the patients given zinc were one and a half times more likely to recover, decreasing their need for intensive care.